WithdrawnEarly Phase 1

HDAC Inhibitor Augmentation to Clozapine

Stopped: PIs were unable to recruit any participants

0Started 2017-04

Plain-language summary

The main goal of this pilot study is to test the extent to which adjunctive treatment with the histone deacetylase (HDAC) inhibitor vorinostat improves brain plasticity and cognition in a pilot placebo-controlled trial in patients with schizophrenia who are on clozapine.

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with DSM-5 Schizophrenia * Receiving stable dose pf clozapine (≥ 300 mg per day) for at least 6 months before entering the study Exclusion Criteria: * Taking specific psychotropic medications (lamotrigine and valproic acid) * Current or recent (12-months) substance use or induced disorder * History of significant neurological or medical disorders * Intellectual disability * Known contraindications to the administration of vorinostat per product labeling * Women currently pregnant, planning to become pregnant, or receiving hormone therapy and refusing any form of birth control

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

Timeframe: 10 weeks

Change in clinical cognitive symptoms during adjunctive vorinostat therapy in schizophrenia patients treated with clozapine

Timeframe: Baseline, Visit 4 (end of first intervention group/week 4), Visit 7 (end of study/10 weeks)

Trial details

NCT IDNCT03263533

SponsorVirginia Commonwealth University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-02

View on ClinicalTrials.gov More Schizophrenia trials